Healthcare of Ontario Pension Plan Trust Fund Buys 62,374 Shares of Thermo Fisher Scientific Inc. $TMO

Healthcare of Ontario Pension Plan Trust Fund grew its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 104.4% in the 4th quarter, Holdings Channel.com reports. The fund owned 122,122 shares of the medical research company’s stock after purchasing an additional 62,374 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Thermo Fisher Scientific were worth $70,764,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of TMO. Norges Bank bought a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at about $3,072,744,000. Wellington Management Group LLP grew its holdings in shares of Thermo Fisher Scientific by 88.9% in the 3rd quarter. Wellington Management Group LLP now owns 2,699,460 shares of the medical research company’s stock valued at $1,309,292,000 after acquiring an additional 1,270,191 shares in the last quarter. Franklin Resources Inc. grew its holdings in shares of Thermo Fisher Scientific by 21.0% in the 3rd quarter. Franklin Resources Inc. now owns 5,925,671 shares of the medical research company’s stock valued at $2,874,069,000 after acquiring an additional 1,028,125 shares in the last quarter. Nuveen LLC grew its holdings in shares of Thermo Fisher Scientific by 65.0% in the 4th quarter. Nuveen LLC now owns 2,147,296 shares of the medical research company’s stock valued at $1,244,251,000 after acquiring an additional 846,111 shares in the last quarter. Finally, Corient Private Wealth LLC grew its holdings in shares of Thermo Fisher Scientific by 89.1% in the 2nd quarter. Corient Private Wealth LLC now owns 1,752,607 shares of the medical research company’s stock valued at $720,576,000 after acquiring an additional 825,649 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Down 0.1%

Shares of TMO stock opened at $468.80 on Monday. The firm has a 50 day moving average price of $479.14 and a two-hundred day moving average price of $527.27. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. The company has a market capitalization of $174.22 billion, a PE ratio of 25.77, a price-to-earnings-growth ratio of 2.08 and a beta of 0.88. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.25 by $0.19. The firm had revenue of $11.01 billion during the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period last year, the business posted $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 24.85 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Monday, June 15th will be given a dividend of $0.47 per share. The ex-dividend date is Monday, June 15th. This represents a $1.88 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.34%.

Analyst Ratings Changes

TMO has been the subject of several analyst reports. Royal Bank Of Canada set a $490.00 price objective on Thermo Fisher Scientific and gave the company a “sector perform” rating in a report on Thursday, May 14th. DZ Bank started coverage on Thermo Fisher Scientific in a report on Friday, March 27th. They set a “buy” rating and a $610.00 price target for the company. Wolfe Research started coverage on Thermo Fisher Scientific in a report on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 price target for the company. HSBC cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating and reduced their price target for the stock from $670.00 to $540.00 in a report on Wednesday, June 3rd. Finally, Barclays reduced their price target on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating for the company in a report on Tuesday, April 14th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $608.95.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the sale, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. This trade represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by company insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.